Bispecific antibodies (BsAbs) are an emerging class of engineered biologics designed to simultaneously bind two distinct antigens or epitopes. By enabling dual-target engagement, bispecific antibodies offer unique mechanisms of action that extend beyond conventional monoclonal antibodies, particularly in oncology and immuno-oncology. In recent years, advances in protein engineering, manufacturing, and clinical development have accelerated the translation of bispecific antibodies from experimental concepts into approved therapies and late-stage clinical candidates.

Clinical Advances in Oncology

One of the most active areas for bispecific antibody development is cancer therapy. T-cell–engaging bispecific antibodies, which simultaneously bind a tumor-associated antigen and the CD3 receptor on T cells, have demonstrated substantial clinical efficacy in hematologic malignancies. For example, several BCMA × CD3 bispecific antibodies have shown high response rates in relapsed or refractory multiple myeloma, leading to regulatory approvals and expanded clinical adoption [1,2].

Beyond hematologic cancers, bispecific antibodies are increasingly being developed for solid tumors. Zanidatamab, a HER2 × HER2 bispecific antibody that binds two distinct epitopes on the HER2 receptor, has demonstrated encouraging clinical activity in HER2-positive biliary tract and gastrointestinal cancers [3]. Similarly, zenocutuzumab, a HER2 × HER3 bispecific antibody, has shown durable responses in patients with NRG1 gene fusion–driven tumors, addressing a rare oncogenic driver with limited therapeutic options [4].

Next-Generation Bispecific Designs and Combinations

Recent scientific efforts have focused on next-generation bispecific designs aimed at improving efficacy while reducing toxicity. Novel formats seek to optimize binding affinity, spatial geometry, and half-life to mitigate adverse effects such as cytokine release syndrome commonly associated with T-cell engagers. Additionally, bispecific antibodies targeting immune checkpoints and angiogenic pathways, such as PD-L1 × VEGF bispecifics, are being explored as alternatives or complements to combination monoclonal antibody therapies [5].

Strategic collaborations between biotechnology companies and large pharmaceutical firms have further accelerated development. These partnerships often combine proprietary bispecific platforms with extensive clinical and manufacturing expertise, enabling rapid progression into late-stage trials.

Challenges and Development Considerations

Despite their promise, bispecific antibodies present unique challenges. Manufacturing complexity, stability issues, and safety concerns remain key hurdles. Recent discontinuations of certain bispecific programs highlight the importance of careful target selection and clinical strategy, particularly in solid tumors where immune-related toxicities can limit therapeutic windows [6].

Outlook

The growing number of approved bispecific antibodies and late-stage clinical candidates underscores the maturation of this therapeutic modality. Ongoing innovations in antibody engineering and clinical trial design are expected to further expand the applications of bispecific antibodies beyond oncology, including autoimmune and infectious diseases. As the field continues to evolve, bispecific antibodies are poised to play an increasingly important role in precision medicine.

---

References

1. Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019). Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 18(8), 585–608.
2. Krishnamurthy, A., et al. (2024). Clinical development of T-cell–redirecting bispecific antibodies in multiple myeloma. Blood, 143(5), 401–414.
3. Meric-Bernstam, F., et al. (2023). Zanidatamab in HER2-expressing biliary tract and gastrointestinal cancers. The Lancet Oncology, 24(7), 895–907.
4. Schram, A. M., et al. (2022). Zenocutuzumab for NRG1 fusion–positive cancers. New England Journal of Medicine, 387(2), 135–146.
5. Goebeler, M.-E., & Bargou, R. C. (2020). T cell-engaging therapies—BiTEs and beyond. Nature Reviews Clinical Oncology, 17(7), 418–434.
6. Mullard, A. (2024). Bispecific antibodies hit growing pains in solid tumors. Nature Reviews Drug Discovery, 23(1), 6–8.